The DOI matches its OpenAlex record; 23 of the 23 references it cites were found in a registry or an index.
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
Open accessAbstract
Loss of DNA mismatch repair because of hypermethylation of the hMLH1 gene promoter occurs at a high frequency in a number of human tumors. A role for loss of mismatch repair (MMR) in resistance to a number of clinically important anticancer drugs has been shown. We have investigated whether the demethylating agent 2'-deoxy-5-azacytidine (DAC) can be used in vivo to sensitize MMR-deficient, drug-resistant ovarian (A2780/cp70) and colon (SW48) tumor xenografts that are MLH1 negative because of gene promoter hypermethylation. Treatment of tumor-bearing mice with the demethylating agent DAC at a nontoxic dose induces MLH1 expression. Re-expression of MLH1 is associated with a decrease in hMLH1 gene promoter methylation. DAC treatment alone has no effect on the growth rate of the tumors. However, DAC treatment sensitizes the xenografts to cisplatin, carboplatin, temozolomide, and epirubicin. Sensitization is comparable with that obtained by reintroduction of the hMLH1 gene by chromosome 3 transfer. Consistent with loss of MMR having no effect on sensitivity in vitro to Taxol, DAC treatment has no effect on the Taxol sensitivity of the xenografts. DAC treatment does not sensitize xenografts of HCT116, which lacks MMR because of hMLH1 mutation. Because there is emerging data on the role of loss of MMR in clinical drug resistance, DAC could have a role in increasing the efficacy of chemotherapy for patients whose tumors lack MLH1 expression because of hMLH1 promoter methylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Jüttermann, R., Li, E., & Jaenisch, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.11797 · Cited by 678
How does DNA methylation repress transcription?
Kass, S. U., Pruss, D., & Wolffe, A. P. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01268-7 · Cited by 535
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 410
Bender, C. M., Pao, M. M., & Jones, P. A. (1998) · PubMed · Cited by 380
Leung, S. Y., Yuen, S. T., Chung, L.-P., Chu, K., Chan, A. S. Y., & Ho, J. C. I. (1999) · PubMed · Cited by 365
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Self-citationDependence of transcriptional repression on CpG methylation density.
Hsieh, C. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5487 · Cited by 300
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Das, P. M., & Singal, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.151 · Cited by 1,456
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Self-citationApoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedDNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISM
Esteller, M. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095832 · Cited by 549
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
Lyko, F., & Brown, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji311 · Cited by 510
Self-citationHabtemariam, A., Melchart, M., Fernández, R., Parsons, S., Oswald, I. D. H., Parkin, A., Fabbiani, F. P. A., Davidson, J. E., Dawson, A., Aird, R. E., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060596m · Cited by 456
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Relevance of DNA methylation in the management of cancer
Esteller, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01115-x · Cited by 329
Defining Driver DNA Methylation Changes in Human Cancer
Pfeifer, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041166 · Cited by 323
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 303
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Self-citationDNA Methylation as a Therapeutic Target in Cancer
Issa, J.-P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2076 · Cited by 301
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Zeller, C., Dai, W., Steele, N. L., Siddiq, A., Walley, A. J., Wilhelm-Benartzi, C. S. M., Rizzo, S., van der Zee, A., Plumb, J. A., & Brown, R. (2012) · Oncogene · doi:10.1038/onc.2011.611 · Cited by 285
Self-citationDrug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Arnold, C. N., Goel, A., & Boland, C. R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11176 · Cited by 280
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., Brown, R., & on behalf of the Scottish Gynaecological Clinical Trials Group (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262
Self-citationEpigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236
Self-citationZebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer
Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2130 · Cited by 93
Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications
Xiao, X., Melton, D. W., & Gourley, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.003 · Cited by 89
Cell signaling and cancer: a mechanistic insight into drug resistance
Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89
Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
Quagliano, A., Gopalakrishnapillai, A., & Barwe, S. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00992 · Cited by 56
Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., & Sugihara, K. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9285-4 · Cited by 43
The Synergistic Effect of 5-Aza-2′-Deoxycytidine and 5-Fluorouracil on Drug-Resistant Tumors
Morita, S., Iida, S., Kato, K., Takagi, Y., Uetake, H., & Sugihara, K. (2006) · Oncology · doi:10.1159/000107110 · Cited by 29
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28
Metadata
- Authors
- Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2000-12-31
- Volume
- 60
- Issue
- 21
- Pages
- 6039-44
- OpenAlex
- W1546270188
- Cited by
- 486
- References
- 23
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.